{"id":7920,"date":"2025-09-23T15:32:09","date_gmt":"2025-09-23T15:32:09","guid":{"rendered":"https:\/\/stoxpo.com\/?p=7920"},"modified":"2025-09-23T15:32:09","modified_gmt":"2025-09-23T15:32:09","slug":"kenvue-rebounds-after-tylenol-autism-claims-spark-market-jitters","status":"publish","type":"post","link":"https:\/\/stoxpo.com\/index.php\/2025\/09\/23\/kenvue-rebounds-after-tylenol-autism-claims-spark-market-jitters\/","title":{"rendered":"Kenvue Rebounds After Tylenol Autism Claims Spark Market Jitters"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\">Analysts cite lack of new scientific evidence as shares recover from record low<\/h4>\n\n\n\n<p class=\"wp-block-paragraph\">Kenvue (KVUE) shares rose 6% on Tuesday, recovering from an all-time low in the previous session after President Donald Trump linked the company\u2019s flagship product, Tylenol, to autism without presenting new scientific evidence. The rebound reflected investor relief that health regulators and experts quickly reaffirmed the safety of acetaminophen, the active ingredient in Tylenol.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">On Monday, Trump elevated concerns by suggesting both childhood vaccines and maternal use of Tylenol during pregnancy could be tied to autism. The comments triggered a sharp selloff in Kenvue\u2019s stock, as investors feared regulatory or legal consequences. However, analysts noted that no new data was introduced to support these claims.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cInvestors were holding their breath worried that yesterday\u2019s announcement would be a bombshell. It turned out it wasn\u2019t, as no new scientific evidence was presented,\u201d said James Harlow, vice president at Novare Capital Management.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Health agencies in the European Union and the United Kingdom reaffirmed the safety of paracetamol during pregnancy, while the World Health Organization said evidence of any link remains inconsistent. Kenvue itself reiterated that acetaminophen has no proven connection to autism, warning that spreading misinformation could pose risks to maternal health.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Tylenol is a crucial product for Kenvue, generating about $1 billion annually in sales, according to Morningstar estimates. While Citi analysts acknowledged the potential for negative headlines to impact consumer sentiment, they see limited judicial risk.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The Food and Drug Administration announced plans to update Tylenol and generic labels to reference existing research on possible neurological risks, but emphasized that no causal relationship has been established.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">\u201cThis issue only involves pregnant mothers, which is a smaller subset of consumers\u2014so the actual impact on Kenvue\u2019s financials was always likely to be modest,\u201d Harlow added.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Kenvue, spun off from Johnson &amp; Johnson in 2023, appears to have weathered the immediate market fallout, though scrutiny over maternal drug safety may continue.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">You might like this article:<a href=\"https:\/\/stoxpo.com\/index.php\/2025\/09\/22\/oracle-rises-on-tiktok-deal-and-leadership-shakeup\/\"><mark style=\"background-color:rgba(0, 0, 0, 0)\" class=\"has-inline-color has-vivid-cyan-blue-color\">Oracle Rises on TikTok Deal and Leadership Shakeup<\/mark><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Analysts cite lack of new scientific evidence as shares recover from record low Kenvue (KVUE) shares rose 6% on Tuesday, recovering from an all-time low in the previous session after President Donald Trump linked the company\u2019s flagship product, Tylenol, to autism without presenting new scientific evidence. The rebound reflected investor relief that health regulators and [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":1138,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jnews-multi-image_gallery":[],"jnews_single_post":[],"jnews_primary_category":[],"jnews_social_meta":[],"jnews_override_counter":[],"jnews_post_split":[],"footnotes":""},"categories":[309],"tags":[421,816,416,418,417],"coauthors":[454],"class_list":["post-7920","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pharmaceuticals","tag-growth","tag-kvue","tag-movers","tag-news","tag-stock-market"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Kenvue Rebounds After Tylenol Autism Claims Spark Market Jitters - Stoxpo<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/stoxpo.com\/index.php\/2025\/09\/23\/kenvue-rebounds-after-tylenol-autism-claims-spark-market-jitters\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kenvue Rebounds After Tylenol Autism Claims Spark Market Jitters - Stoxpo\" \/>\n<meta property=\"og:description\" content=\"Analysts cite lack of new scientific evidence as shares recover from record low Kenvue (KVUE) shares rose 6% on Tuesday, recovering from an all-time low in the previous session after President Donald Trump linked the company\u2019s flagship product, Tylenol, to autism without presenting new scientific evidence. The rebound reflected investor relief that health regulators and [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/stoxpo.com\/index.php\/2025\/09\/23\/kenvue-rebounds-after-tylenol-autism-claims-spark-market-jitters\/\" \/>\n<meta property=\"og:site_name\" content=\"Stoxpo\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-23T15:32:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-anna-shvets-3683100-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Luca Blaumann\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Luca Blaumann\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/09\\\/23\\\/kenvue-rebounds-after-tylenol-autism-claims-spark-market-jitters\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/09\\\/23\\\/kenvue-rebounds-after-tylenol-autism-claims-spark-market-jitters\\\/\"},\"author\":{\"name\":\"Luca Blaumann\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/031a96817fc4447b1046e0a10baad806\"},\"headline\":\"Kenvue Rebounds After Tylenol Autism Claims Spark Market Jitters\",\"datePublished\":\"2025-09-23T15:32:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/09\\\/23\\\/kenvue-rebounds-after-tylenol-autism-claims-spark-market-jitters\\\/\"},\"wordCount\":345,\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/09\\\/23\\\/kenvue-rebounds-after-tylenol-autism-claims-spark-market-jitters\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-anna-shvets-3683100-scaled.jpg\",\"keywords\":[\"Growth\",\"KVUE\",\"Movers\",\"News\",\"Stock Market\"],\"articleSection\":[\"Pharmaceuticals\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/09\\\/23\\\/kenvue-rebounds-after-tylenol-autism-claims-spark-market-jitters\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/09\\\/23\\\/kenvue-rebounds-after-tylenol-autism-claims-spark-market-jitters\\\/\",\"name\":\"Kenvue Rebounds After Tylenol Autism Claims Spark Market Jitters - Stoxpo\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/09\\\/23\\\/kenvue-rebounds-after-tylenol-autism-claims-spark-market-jitters\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/09\\\/23\\\/kenvue-rebounds-after-tylenol-autism-claims-spark-market-jitters\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-anna-shvets-3683100-scaled.jpg\",\"datePublished\":\"2025-09-23T15:32:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/09\\\/23\\\/kenvue-rebounds-after-tylenol-autism-claims-spark-market-jitters\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/09\\\/23\\\/kenvue-rebounds-after-tylenol-autism-claims-spark-market-jitters\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/09\\\/23\\\/kenvue-rebounds-after-tylenol-autism-claims-spark-market-jitters\\\/#primaryimage\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-anna-shvets-3683100-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/pexels-anna-shvets-3683100-scaled.jpg\",\"width\":2560,\"height\":1707,\"caption\":\"drugs-4\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/2025\\\/09\\\/23\\\/kenvue-rebounds-after-tylenol-autism-claims-spark-market-jitters\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/stoxpo.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kenvue Rebounds After Tylenol Autism Claims Spark Market Jitters\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#website\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"name\":\"Stoxpo\",\"description\":\"Stock Market &amp; Financial News\",\"publisher\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/stoxpo.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#organization\",\"name\":\"Stoxpo\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"contentUrl\":\"https:\\\/\\\/stoxpo.com\\\/wp-content\\\/uploads\\\/2024\\\/02\\\/4q4p91-LogoMakr.png\",\"width\":250,\"height\":250,\"caption\":\"Stoxpo\"},\"image\":{\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/stoxpo.com\\\/#\\\/schema\\\/person\\\/031a96817fc4447b1046e0a10baad806\",\"name\":\"Luca Blaumann\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g90dbb3a40c7379bca26d2b3dc92b368b\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g\",\"caption\":\"Luca Blaumann\"},\"description\":\"Luca is a proficient stock market reporter with a passion for dissecting complex market dynamics and uncovering transformative industry developments. With years of experience in leading editorial teams and overseeing coverage of the stock market and publicly traded companies, Luca has honed the ability to translate finance jargon into easily digestible articles. For tips and inquiries, reach out to Luca at tips@stoxpo.com.\",\"url\":\"https:\\\/\\\/stoxpo.com\\\/index.php\\\/author\\\/luca-blaumann\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kenvue Rebounds After Tylenol Autism Claims Spark Market Jitters - Stoxpo","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/stoxpo.com\/index.php\/2025\/09\/23\/kenvue-rebounds-after-tylenol-autism-claims-spark-market-jitters\/","og_locale":"en_US","og_type":"article","og_title":"Kenvue Rebounds After Tylenol Autism Claims Spark Market Jitters - Stoxpo","og_description":"Analysts cite lack of new scientific evidence as shares recover from record low Kenvue (KVUE) shares rose 6% on Tuesday, recovering from an all-time low in the previous session after President Donald Trump linked the company\u2019s flagship product, Tylenol, to autism without presenting new scientific evidence. The rebound reflected investor relief that health regulators and [&hellip;]","og_url":"https:\/\/stoxpo.com\/index.php\/2025\/09\/23\/kenvue-rebounds-after-tylenol-autism-claims-spark-market-jitters\/","og_site_name":"Stoxpo","article_published_time":"2025-09-23T15:32:09+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-anna-shvets-3683100-scaled.jpg","type":"image\/jpeg"}],"author":"Luca Blaumann","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Luca Blaumann","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/stoxpo.com\/index.php\/2025\/09\/23\/kenvue-rebounds-after-tylenol-autism-claims-spark-market-jitters\/#article","isPartOf":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/09\/23\/kenvue-rebounds-after-tylenol-autism-claims-spark-market-jitters\/"},"author":{"name":"Luca Blaumann","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/031a96817fc4447b1046e0a10baad806"},"headline":"Kenvue Rebounds After Tylenol Autism Claims Spark Market Jitters","datePublished":"2025-09-23T15:32:09+00:00","mainEntityOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/09\/23\/kenvue-rebounds-after-tylenol-autism-claims-spark-market-jitters\/"},"wordCount":345,"publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/09\/23\/kenvue-rebounds-after-tylenol-autism-claims-spark-market-jitters\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-anna-shvets-3683100-scaled.jpg","keywords":["Growth","KVUE","Movers","News","Stock Market"],"articleSection":["Pharmaceuticals"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/stoxpo.com\/index.php\/2025\/09\/23\/kenvue-rebounds-after-tylenol-autism-claims-spark-market-jitters\/","url":"https:\/\/stoxpo.com\/index.php\/2025\/09\/23\/kenvue-rebounds-after-tylenol-autism-claims-spark-market-jitters\/","name":"Kenvue Rebounds After Tylenol Autism Claims Spark Market Jitters - Stoxpo","isPartOf":{"@id":"https:\/\/stoxpo.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/09\/23\/kenvue-rebounds-after-tylenol-autism-claims-spark-market-jitters\/#primaryimage"},"image":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/09\/23\/kenvue-rebounds-after-tylenol-autism-claims-spark-market-jitters\/#primaryimage"},"thumbnailUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-anna-shvets-3683100-scaled.jpg","datePublished":"2025-09-23T15:32:09+00:00","breadcrumb":{"@id":"https:\/\/stoxpo.com\/index.php\/2025\/09\/23\/kenvue-rebounds-after-tylenol-autism-claims-spark-market-jitters\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/stoxpo.com\/index.php\/2025\/09\/23\/kenvue-rebounds-after-tylenol-autism-claims-spark-market-jitters\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/index.php\/2025\/09\/23\/kenvue-rebounds-after-tylenol-autism-claims-spark-market-jitters\/#primaryimage","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-anna-shvets-3683100-scaled.jpg","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/pexels-anna-shvets-3683100-scaled.jpg","width":2560,"height":1707,"caption":"drugs-4"},{"@type":"BreadcrumbList","@id":"https:\/\/stoxpo.com\/index.php\/2025\/09\/23\/kenvue-rebounds-after-tylenol-autism-claims-spark-market-jitters\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/stoxpo.com\/"},{"@type":"ListItem","position":2,"name":"Kenvue Rebounds After Tylenol Autism Claims Spark Market Jitters"}]},{"@type":"WebSite","@id":"https:\/\/stoxpo.com\/#website","url":"https:\/\/stoxpo.com\/","name":"Stoxpo","description":"Stock Market &amp; Financial News","publisher":{"@id":"https:\/\/stoxpo.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/stoxpo.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/stoxpo.com\/#organization","name":"Stoxpo","url":"https:\/\/stoxpo.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/","url":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","contentUrl":"https:\/\/stoxpo.com\/wp-content\/uploads\/2024\/02\/4q4p91-LogoMakr.png","width":250,"height":250,"caption":"Stoxpo"},"image":{"@id":"https:\/\/stoxpo.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/stoxpo.com\/#\/schema\/person\/031a96817fc4447b1046e0a10baad806","name":"Luca Blaumann","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g90dbb3a40c7379bca26d2b3dc92b368b","url":"https:\/\/secure.gravatar.com\/avatar\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b7bbde6ef0582da5f93c9ff12262ea37de640f314250f9e3cfaeb37e258a563a?s=96&d=mm&r=g","caption":"Luca Blaumann"},"description":"Luca is a proficient stock market reporter with a passion for dissecting complex market dynamics and uncovering transformative industry developments. With years of experience in leading editorial teams and overseeing coverage of the stock market and publicly traded companies, Luca has honed the ability to translate finance jargon into easily digestible articles. For tips and inquiries, reach out to Luca at tips@stoxpo.com.","url":"https:\/\/stoxpo.com\/index.php\/author\/luca-blaumann\/"}]}},"_links":{"self":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/7920","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/comments?post=7920"}],"version-history":[{"count":2,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/7920\/revisions"}],"predecessor-version":[{"id":7922,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/posts\/7920\/revisions\/7922"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media\/1138"}],"wp:attachment":[{"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/media?parent=7920"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/categories?post=7920"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/tags?post=7920"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/stoxpo.com\/index.php\/wp-json\/wp\/v2\/coauthors?post=7920"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}